Editorji is a popular short video news and information platform based in India. It was founded in 2018 by Vikram Chandra, one of India’s leading journalists, and has risen to prominence in the digital news space in a relatively short span of time. The platform is primarily designed for mobile devices, with applications available for Android and iOS.

ABOUT US:

about us editorji

Latest Video News: Editorji provides the latest news video headlines, latest videos clip from India and the World. Get all breaking news videos on Entertainment, Business, Coronavirus, Elections, Politics and more.

Latest Video News, Breaking News, Bollywood, Political, Sports, Business News | Editorji

+91 11 4035 6666 / info@editorji.com
3rd floor, Plot B, Khasara no 360, Sultanpur, New Delhi, Delhi 110030
<a title="mail to us" href="mailto:info@editorji.com">Send Feedback</a>
<a title="Contact Us" href="mailto:info@editorji.com">Contact Us</a>

REACH US

Contact for any questions, suggestions, comments, feedback or advertisement on Editorji.com, we are always looking forward to hearing from you.

Contact Us for Feedback, Suggestions and Advertising 

Editorji content is better experienced in our app.

Professor Sarah Gilbert, creator of AstraZeneca&nbsp;vaccine said that Covid-19 is unlikely mutate into a deadlier variant.&nbsp;
It will eventually just be a 'common cold', just like four other coronaviruses&nbsp;that circulate widely in the air.&nbsp;
Speaking at Royal Medical Society seminar, she also said that work on a tweaked vaccine against Beta variant only gave 'slightly better' immune response. However, data is still being collected on it.&nbsp;
Professor Gilbert's comments come just as Professor Chris Witty, Chief Medical Officer of England warned that non&nbsp;vaccinated children are at a risk of contracting Covid-19 at least once.&nbsp;

'Covid is going to just become a cold': creator of AstraZeneca vaccine, Sarah Gilbert

Professor Sarah Gilbert, the creator of life saving AstraZeneca&nbsp;vaccine has said that Covid-19 will eventually just be a 'common cold'. Watch this report

Professor Sarah Gilbert, the creator of AstraZeneca&nbsp;vaccine has said that Covid-19 is unlikely mutate into a deadlier variant.&nbsp;
She said it will eventually just be a 'common cold', just like four other coronaviruses&nbsp;that circulate widely in the air.&nbsp;
Speaking at Royal Medical Society seminar, she also said that work on a tweaked vaccine against Beta variant only gave 'slightly better' immune response. However, data is still being collected on it.&nbsp;
Gilbert's comments come just as Professor Chris Witty, the Chief Medical Officer of England warned that non&nbsp;vaccinated children are at a risk of contracting Covid-19 at least once.&nbsp;

At a Royal Society of Medicine seminar Professor Gilbert said that Covid-19 will eventually just be a common cold similar to other coronaviruses. The CMO&nbsp;of Eng comments all unvaccinated&nbsp;children to get coronavirus&nbsp;once.&nbsp;

Professor Sarah Gilbert, the creator of AstraZeneca&nbsp;vaccine has said that Covid-19 is unlikely to mutate into a deadlier variant.&nbsp;
It will eventually just be a 'common cold', just like four other coronaviruses&nbsp;that circulate widely in the air, she added.&nbsp;
Speaking at Royal Medical Society seminar, she also said that work on a tweaked vaccine against Beta variant only gave 'slightly better' immune response. However, data is still being collected on it.&nbsp;
Professor Gilbert's comments come just as Professor Chris Witty, Chief Medical Officer of England warned that non&nbsp;vaccinated children are at a risk of contracting Covid-19 at least once.&nbsp;

In UK, most adults under the age of 40 will be given an alternative to the Oxford-AstraZeneca Covid-19 vaccine due to a link with rare blood clots. The country&rsquo;s medicines safety regulator said there have been 242 clotting cases and 49 deaths, with 28.5 million doses of the vaccine administered.
However, the risk is slightly higher in younger age groups. The risk of a clot is roughly one in 100,000 for people in their 40s, but rises to one in 60,000 for people in their 30s. Two in a million people in their 40s died rising to four per million people in their 30s.
The supply of alternative vaccines, including Pfizer and Moderna, has made the decision possible.

Blood clot risks: In UK under 40s to be offered alternative to AstraZeneca Covid vaccine

In UK under 40s to be offered alternative to AstraZeneca Covid vaccine

AstraZeneca&nbsp;vaccine alternative for under 40s in UK
Alternative given due to vaccine's link to blood clots
Risk of a blood clot higher in younger age
Supply of&nbsp;alternative vaccines also facilitates decision
&nbsp;
&nbsp;

In UK, most adults under the age of 40 will be given an alternative to the Oxford-AstraZeneca Covid-19 vaccine due to a link with rare blood clots. The country&rsquo;s medicines safety regulator said there have been 242 clotting cases and 49 deaths, with 28.5 million doses of the vaccine administered.
However, the risk is slightly higher in younger age groups. The risk of a clot is roughly one in 100,000 for people in their 40s, but rises to one in 60,000 for people in their 30s. Two in a million people in their 40s died rising to four per million people in their 30s.
The supply of alternative vaccines, including Pfizer and Moderna, has made the decision possible.

A trial of the Oxford/AstraZeneca Covid-19 vaccine on children has been paused while the UK's medicines regulator investigates a possible link with rare blood clots in adults.
The move came as further reports emerged around rare blood clots, after a European Medicines Agency official indicated there appeared to be some link with the jab.
Earlier on Tuesday, UK Prime Minister Boris Johnson urged people to continue taking their Oxford/AstraZeneca vaccines. The country's medicines regulator has maintained that the benefits of the vaccine continue to outweigh any rare concerns.

UK: AstraZeneca's Covid vaccine's children's trial paused amid blood clots concerns

A trial of the Oxford/AstraZeneca Covid-19 vaccine on children has been paused while the UK's medicines regulator investigates a possible link with rare blood clots in adults.

UK: AstraZeneca children's trial paused amid blood clots concerns

A trial of the Oxford/AstraZeneca Covid-19 vaccine on children has been paused while the UK's medicines regulator investigates a possible link with rare blood clots in adults. The move came as further reports emerged around rare blood clots, after a European Medicines Agency official indicated there appeared to be some link with the jab. Earlier on Tuesday, UK Prime Minister Boris Johnson urged people to continue taking their Oxford/AstraZeneca vaccines. The country's medicines regulator has maintained that the benefits of the vaccine continue to outweigh any rare concerns.

A trial of the Oxford/AstraZeneca Covid-19 vaccine on children has been paused while the UK's medicines regulator investigates a possible link with rare blood clots in adults.
The move came as further reports emerged around rare blood clots, after a European Medicines Agency official indicated there appeared to be some link with the jab.
Earlier on Tuesday, UK Prime Minister Boris Johnson urged people to continue taking their Oxford/AstraZeneca vaccines. The country's medicines regulator has maintained that the benefits of the vaccine continue to outweigh any rare concerns.

Oxford vaccine trial volunteer who died hadn't got dose

A participant who died during a trial of AstraZeneca-Oxford's Covid-19 vaccine in Brazil hadn't received the company's shot, news agency Bloomberg has reported quoting a person familiar with the matter

A participant who died during a trial of AstraZeneca-Oxford's Covid-19 vaccine in Brazil hadn't received the company's shot, news agency Bloomberg has reported quoting a person familiar with the matter. Brazil's health authority had said that a volunteer for the vaccine trial had died on Monday. The regulator said testing of the vaccine would continue after the volunteer's death. It provided no further details, citing medical confidentiality of those involved in trials. The Federal University of Sao Paulo, which is helping coordinate phase 3 clinical trials in Brazil, separately said that the volunteer was Brazilian but did not say where the person lived.

astrazeneca oxford

Categories